Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03

PURPOSE: Rituximab maintenance therapy has been shown to improve progression-free survival in patients with follicular lymphoma; however, the optimal duration of maintenance treatment remains unknown. PATIENTS AND METHODS: Two hundred seventy patients with untreated, relapsed, stable, or chemotherap...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Taverna, Christian, Martinelli, Giovanni, Hitz, Felicitas, Mingrone, Walter, Pabst, Thomas, Cevreska, Lidija, del Giglio, Auro, Vanazzi, Anna, Laszlo, Daniele, Raats, Johann, Rauch, Daniel, Vorobiof, Daniel A., Lohri, Andreas, Biaggi Rudolf, Christine, Rondeau, Stéphanie, Rusterholz, Corinne, Heijnen, Ingmar A.F.M., Zucca, Emanuele, Ghielmini, Michele
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2016
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4872010/
https://ncbi.nlm.nih.gov/pubmed/26712227
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2015.61.3968
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados